Treatment of Cerebral Toxoplasmosis in HIV/AIDS

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Neurological manifestations of Cerebral toxoplasmosis or Toxoplasmic encephalitis (TE) in most advance stage HIV infected patients composed of fever, headache, alteration of consciousness with focal neurological signs/symptoms such as include hemiparesis, cranial nerve palsies, and ataxia. Generalised convulsions, in ¾ of patients. Moreover meningeal irritation sign or herniation sign may be presented as life threatening condition

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rajavithi Hospital
• Collaborator: Chiang Mai University
• Treatments: Pyrimethamine; Sulfadiazine; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

• AIDS

• Age > 16 years

• Clinical Diagnosis of Cerebral toxoplasmosis, Toxoplasmic encephalitis

• Positive serum titer for Toxoplasma gondii or Positive CSF titer for Toxoplasma gondii after treatment within 2 weeks

• CT scan suspected toxoplasmosis, ring enhancing lesion

• CD4<200

Exclusion Criteria:

• Sulfa drugs allergy

• positive lymphoma cell cytology in CSF

• no informed consent by patients or first degreee relatives

• CD4 >200